Company: SWKH
Filing Date: 2025-04-29
Form Type: ARS
Source: 0001628280-25-020753
Chunk: 103

Company: SWK Holdings Corp
Filing Date: 2025-04-29
Form: ARS
Chunk 103
---
 management organizes the segments within the Company for making operating decisions, allocating resources, and assessing performance. Consequently, the segments are evident from the structure of the Company’s internal organization, focusing on financial information that the Company’s CEO uses to make decisions about the Company’s operating matters.

As described in Note 1, SWK Holdings Corporation and Summary of Significant Accounting Policies, the Company has determined it has two reportable segments: Finance Receivables and Pharmaceutical Development, and each are individually managed and provide separate services. Revenues by segment represent revenues earned on the services offered within each segment. The Company does not report results by geographic region, as this metric is not used by the Company’s chief executive officer in assessing performance or allocating resources to the segments. All revenues are generated through external customers.

Segment performance is evaluated based on several factors, including income (loss) from continuing operations before income taxes. Management uses this measure of profit (loss) to evaluate segment performance because the Company believes this measure is indicative of performance trends and the overall earnings potential of each segment. The Company does not report assets by reportable segment, as this metric is not used by the Company's CEO in assessing performance or allocating resources to the segments. As of December 31, 2024, Enteris is classified as held for sale (Pharmaceutical Development segment shown below) - see Note 7 for further details.

<div align='center'>65</div>

The following tables present financial information for the Company’s reportable segments for the periods indicated (in thousands):

|                                                                      |     | Year Ended December 31, 2024 |        |     |                                      |        |     |                           |         |     |              |        |
|:---------------------------------------------------------------------|:----|:-----------------------------|-------:|:----|:-------------------------------------|-------:|:----|:--------------------------|--------:|:----|:-------------|-------:|
|                                                                      |     | Finance Receivables          |        |     | Pharmaceutical Development and Other |        |     | Holding Company and Other |         |     | Consolidated |        |
| Revenue                                                              |     | $                            | 40,787 |     | $                                    |  3,616 |     | $                         |       — |     | $            | 44,403 |
| Other revenue                                                        |     |                              |    553 |     |                                      |     31 |     |                           |       — |     |              |    584 |
| Provision for credit losses